免責聲明: 本站彙整 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公開資料,僅供一般參考,不構成醫療建議、診斷、治療建議或投資建議。

臨床試驗

Safety and Clinical Performance of a Biological Matrix Used in Abdominal Wall Reconstruction

NCT:NCT04580511 · ACTIVE_NOT_RECRUITING

NCT IDNCT04580511
狀態ACTIVE_NOT_RECRUITING
開始日期2020-11-04
SponsorMeccellis Biotech (INDUSTRY)
First posted
Last updated

簡要摘要

The general objective of the study is to confirm the medium/long-term safety and clinical performance of the CELLIS membrane used in abdominal wall reconstruction including, but not limited to, ventral hernia repair and stoma closure, and to identify emerging risks in comparison to the clinical data related to other types of fixation material. The present study will be a prospective multicentric non-randomized and noncontrolled trial involving 112 patients followed for 24 months. The study will be conducted in France in 3 investigational centres.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。

↑